Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)

Table 4 Most common adverse events that led to treatment discontinuation^a

Gem gemcitabine, nab-P nab-paclitaxel
^aMost frequent was defined as those adverse events occurring in ≥ 5 % of the patients in either treatment arm

ISSN: 1471-2407